Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon

Hepatology

Volumn 53, Issue 4, 2011, Pages 1100-1108

  Di Bisceglie, Adrian M ^a   Stoddard, Anne M ^b   Dienstag, Jules L ^c,d   Shiffman, Mitchell L ^e   Seeff, Leonard B ^f,n   Bonkovsky, Herbert L ^g,h   Morishima, Chihiro ⁱ   Wright, Elizabeth C ^f   Snow, Kristin K ^b   Lee, William M ^j   Fontana, Robert J ^k   Morgan, Timothy R ^l,m   Ghany, Marc G ^f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Bon Secours Health System   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h CAROLINAS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m VA LONG BEACH HEALTHCARE SYSTEM   (United States)

ⁿ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC LIVER DISEASE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DISEASE; HEPATITIS C; HUMAN; INFLUENZA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 79953758508     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24169     Document Type: Article

References (23)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29( Suppl 1): 74-81.
3. Wu C, Chang H-G, McNutt L-A, Smith PF. Estimating the mortality rate of hepatitis C using multiple data sources. Epidemiol Infect 2005; 133: 121-125.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
5. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al.; HALT-C Trial Group. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472-492.
6. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. for the HALT-C Trial Group. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
7. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7: 690-713.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
10. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
11. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
12. Kenny-Walsh E for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-1233.
13. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. HEPATOLOGY 2001; 33: 455-463.
14. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-749.
15. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212.
16. Neal KR on behalf of the Trent Hepatitis C Study group. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-1104.
17. Toshikuni N, Izumi A, Nishino K, Inada N, Sajanoue R, Yamato R, et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol 2009; 24: 1276-1283.
18. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36( 5 Suppl 1): S35-S46.
19. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-355.
20. Fried MW. Side effects of therapy of hepatitis C and their management. HEPATOLOGY 2002; 36( Suppl): S237-S244.
21. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
22. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972.
23. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim H-Y, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in advanced hepatitis C. Gastroenterology 2011 [Epub ahead of print].